|
Health Condition(s) or Problem
|
Delirium
|
|
Lay Summary
|
Sorry, not currently available
|
|
Who can enter the trial
|
1. Patients over 65 years old
2. Admitted to elderly acute medical ward or orthopaedic ward
3. Patient has a delirium as measured on the Confusion Assessment Method or doesn't have a delirium and has a fractured neck of femur caused by trauma
|
|
Who cannot enter the trial
|
1. Patient already on cholinesterase inhibitor
2. Patient has had a previous adverse reaction to a cholinesterase inhibitor
3. If considered by medical team in charge of care to be in the terminal phase of illness
4. Acute chronic obstructive pulmonary disease (COPD) or asthma
5. Has a dysrhythmia on electrocardiogram (ECG)
6. Urea >20 or creatinine >200
|
|
What will happen
|
Rivastigmine up to 1.5 mg twice a day or placebo.
|
|
Primary aim
|
1. If develops delirium as found on Confusion Assessment Method
2. Length of delirium, measured in days
|
|
Secondary Aim
|
1. Length of admission
2. Change in mini-mental state examination score
3. Use of other psychotropic medication during treatment e.g. benzodiazepines
|
|
Participant Information Sheet
|
Sorry, not currently available
|
|
Website
|
Sorry, not currently available
|
|
Recruitment Status
|
Completed
|
|
Nation
|
England
|
|
Location
|
Manchester
|